pyrazines has been researched along with Lung Adenocarcinoma in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, DS; Fang, Y; Gao, W; Gu, Y; Huang, R; Ma, P; Shu, Y; Wu, X; Zhang, HW | 1 |
| Abreu, RF; Carraro, DM; Cavalher, FP; Corassa, M; Costa, FD; de Lima, VCC; Freitas, HC; Oliveira, TB; Silva, TN; Torrezan, GT | 1 |
| Burns, TF; Camidge, DR; Cetnar, J; Gerber, DE; Horobin, JC; Jeong, W; Keegan, M; Kelly, RJ; Li, M; Morgensztern, D; Ramalingam, SS; Scaglioni, PP; Spigel, DR; Vaikus, L; Weaver, DT; Zhang, S | 1 |
| Amudi, K; Menges, N; Turaçlı, İD; Uygun, MT | 1 |
| Beleggia, F; Büttner, R; Doerr, F; George, J; Hermann, S; Persigehl, T; Rehkämper, T; Reinhardt, HC; Schmitt, A; Thomas, RK; Walter, V; Weber, JP; Wittersheim, M | 1 |
| Chung, A; Guimaraes, PPG; Jacks, T; Langer, R; Mitchell, MJ; Oberli, M; Riley, RS; Spektor, R; Tammela, T; Tan, M; Viana, CTR; Wang, K; Wu, K | 1 |
| Benes, CH; Borgmann, K; Dinkelborg, PH; Gheorghiu, L; Gurski, JM; Hong, TS; Jimenez, RB; Juric, D; Wang, M; Willers, H | 1 |
| Bugaj, JE; Gokhale, PC; Guleryuz, S; Manning, HC; Mantis, C; McKinley, ET; Wild, R; Zhao, P | 1 |
| Bronson, R; Feldser, DM; Jacks, T; Meylan, E; Oliver, TG; Winslow, MM; Xue, W | 1 |
1 trial(s) available for pyrazines and Lung Adenocarcinoma
| Article | Year |
|---|---|
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Focal Adhesion Protein-Tyrosine Kinases; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Proto-Oncogene Proteins p21(ras); Pyrazines; Salvage Therapy; Sulfonamides; Survival Rate | 2020 |
8 other study(ies) available for pyrazines and Lung Adenocarcinoma
| Article | Year |
|---|---|
Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Triazines | 2022 |
Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Pyrazines; Pyrimidines; Triazines | 2022 |
A new synthetic approach for pyrazolo[1,5-a]pyrazine-4(5H)-one derivatives and their antiproliferative effects on lung adenocarcinoma cell line.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Molecular Structure; Pyrazines; Structure-Activity Relationship | 2022 |
Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzodiazepinones; cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrazines; Pyrazoles; RNA, Messenger; Signal Transduction; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2017 |
Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclodextrins; Humans; Lung Neoplasms; Mice, Nude; Pyrazines; Pyridines; Wnt Proteins; Wnt Signaling Pathway | 2018 |
A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
Topics: Adenocarcinoma of Lung; Biopsy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; DNA Breaks, Double-Stranded; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Leukemic; Humans; Lung Neoplasms; MCF-7 Cells; Mutation; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Small Molecule Libraries; Triple Negative Breast Neoplasms | 2019 |
18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Xenograft Model Antitumor Assays | 2011 |
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Lung Neoplasms; Mice; Mice, 129 Strain; NF-kappa B; Nitriles; Pyrazines; Signal Transduction; Sulfones; Survival Rate; Transcription Factor RelA | 2011 |